Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Marc Tessier-Lavigne named Stanford's next president |
||||||||||||||||||
Biotech pioneer Marc Tessier-Lavigne will take charge as Stanford University's next president starting September 1. A former Stanford faculty member and currently the president of Rockefeller University and chairman of Denali Therapeutics, Tessier-Lavigne has spent more than 20 years of his career in the Bay Area, starting as a University of California, San Francisco, assistant professor in 1991. Since then, he has worked as a UCSF professor of anatomy, biochemistry and biophysics, an investigator with the Howard Hughes Medical Institute, a professor of biological sciences at Stanford and in roles of increasing responsibility at Genentech, including CSO and executive vice president of research. Last year, he cofounded San Francisco-based Denali Therapeutics and now serves as chairman. He has served as the president of The Rockefeller University since 2011. At Genentech, he managed 1,400 scientists working in areas such as cancer, immune disorders, infectious diseases and neurodegenerative diseases. As president at Stanford, he'll oversee a research university of 7,000 undergraduates, 9,000 graduate students, 2,100 faculty members at 7 schools and a budget of more than $5.5 billion. Story
|